Effect of Community-Acquired Pneumonia on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Niu, Yuanyuan; Xing, Yanli; Li, Jianfeng; Shui, Wei; Gu, Yuting; Zhang, Changran; Du, Hongchun

doi:10.1080/15412555.2021.1950664

Cited by 6 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were three studies 127,190,238 with sample sizes of less than 20, and another three studies 80,134,194 with sample sizes of 20-40 patients. Moreover, there were three studies 98,119,210 with no females included in the sample, and another 52 studies [20][21][22][23]29,32,38,42,51,53,[68][69][70]72,74,88,90,91,94,116,139,[143][144][145][146][147][148][149]155,159,[161][162][163]173,177,181,182,190,192,193,…”

mentioning

confidence: 99%

Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) – A Systematic Review

Chow,

So,

et al. 2023

COPD

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death globally and is responsible for over 3 million deaths annually. One of the factors contributing to the significant healthcare burden for these patients is readmission. The aim of this review is to describe significant predictors and prediction scores for all-cause and COPD-related readmission among patients with COPD. Methods: A search was conducted in Ovid MEDLINE, Ovid Embase, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials, from database inception to June 7, 2022. Studies were included if they reported on patients at least 40 years old with COPD, readmission data within 1 year, and predictors of readmission. Study quality was assessed. Significant predictors of readmission and the degree of significance, as noted by the p-value, were extracted for each study. This review was registered on PROSPERO (CRD42022337035). Results: In total, 242 articles reporting on 16,471,096 patients were included. There was a low risk of bias across the literature. Of these, 153 studies were observational, reporting on predictors; 57 studies were observational studies reporting on interventions; and 32 were randomized controlled trials of interventions. Sixty-four significant predictors for all-cause readmission and 23 for COPD-related readmission were reported across the literature. Significant predictors included 1) pre-admission patient characteristics, such as male sex, prior hospitalization, poor performance status, number and type of comorbidities, and use of long-term oxygen; 2) hospitalization details, such as length of stay, use of corticosteroids, and use of ventilatory support; 3) results of investigations, including anemia, lower FEV 1 , and higher eosinophil count; and 4) discharge characteristics, including use of home oxygen and discharge to long-term care or a skilled nursing facility. Conclusion:The findings from this review may enable better predictive modeling and can be used by clinicians to better inform their clinical gestalt of readmission risk.

show abstract

mentioning

confidence: 99%

Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) – A Systematic Review

Chow,

So,

et al. 2023

COPD

View full text Add to dashboard Cite

show abstract

“…Further analyses and models were done in the R programming language (v. 4.1) with packages nnet (v. 7. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17], splines (v.4.0.1) and car (v. 3.0-12) (16)(17)(18). The predictive value of the gene expression was analyzed with multinomial models with age as co-variable.…”

Section: Statistical Analysesmentioning

confidence: 99%

“…Significant clinical interaction is seen between the entities of CAP, COPD and AECOPD. Episodes of AECOPD, which may in turn be triggered by CAP, increase the subsequent risk of future exacerbations, all the while conferring an increased risk of morbidity and mortality, driven by the coexistence of COPD and CAP (8,9). Importantly, assessment of the risk for pneumonia in patients with COPD is crucial to determine whether inhaled corticosteroids (ICS) should be given as treatment for COPD, as ICS increase pneumonia risk in these patients (10,11).…”

Section: Introductionmentioning

confidence: 99%

A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients

Bertrams,

Wilhelm,

Veeger

et al. 2024

Front. Med.

View full text Add to dashboard Cite

IntroductionPatients suffering from chronic obstructive pulmonary disease (COPD) are prone to acute exacerbations (AECOPD) or community acquired pneumonia (CAP), both posing severe risk of morbidity and mortality. There is no available biomarker that correctly separates AECOPD from COPD. However, because CAP and AECOPD differ in aetiology, treatment and prognosis, their discrimination would be important.MethodsThis study analysed the ability of selected candidate transcripts from peripheral blood mononuclear cells (PBMCs) to differentiate between patients with AECOPD, COPD & CAP, and CAP without pre-existing COPD.ResultsIn a previous study, we identified differentially regulated genes between CAP and AECOPD in PBMCs. In the present new cohort, we tested the potential of selected candidate PBMC transcripts to differentiate at early time points AECOPD, CAP+COPD, and CAP without pre-existing COPD. Expression of YWHAG, E2F1 and TDRD9 held predictive power: This gene set predicted diseases markedly better (model accuracy up to 100%) than classical clinical markers like CRP, lymphocyte count and neutrophil count (model accuracy up to 82%).DiscussionIn summary, in our cohort expression levels of YWHAG, E2F1 and TDRD9 differentiated with high accuracy between COPD patients suffering from acute exacerbation or CAP.

show abstract

“…ВБП и обострения иногда трудно отличить клинически, в настоящее время не существует четкого консенсуса относительно того, представляют ли они отдельные события или на самом деле являются взаимосвязанными. Клинические исследования показывают, что пациенты с ХОБЛ, госпитализированные с ВБП, имеют более тяжелые симптомы и длительное пребывание в стационаре, в том числе в отделениях интенсивной терапии [5]. Таким образом, проблема ВБП, связанная с ХОБЛ, особенно актуальна, учитывая клинические и экономические аспекты.…”

unclassified

Impact of vaccination with pneumococcal vaccines on recurrent pneumonia in patients with chronic obstructive pulmonary disease

Игнатова

Антонов

2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Background. Community-acquired pneumonia (САР) and chronic obstructive pulmonary disease (COPD) are among the main causes of mortality worldwide, and, in addition, they also lead to great economic losses for the health system of all countries. Currently, there is an increase in cases of recurrent pneumonia, both in the general population and, in particular, in patients with COPD. One of the most important risk factors for the development of pneumonia is the previous episode of САР. Potential risk factors for recurrent pneumonia are concomitant diseases such as heart failure, COPD, diabetes mellitus, neurological disorders, swallowing dysfunction, immune deficiency. Aim. To conduct a retrospective analysis of the effect of vaccine prophylaxis with conjugated pneumococcal vaccine (PCV13) and polysaccharide pneumococcal vaccine (PPV23) on the risk of recurrent pneumonia in patients with COPD. Materials and methods. A total of 302 male patients were included in the retrospective study. When analyzing the data, the fact of the development of pneumonia of any etiology during the 5th observation period was taken into account. For the recurrence of pneumonia, more than two episodes of CAP were taken during the year. 13-valent conjugated pneumococcal vaccine Prevenar-13 and 23-valent polysaccharide vaccine Pneumo23 were used for vaccine prophylaxis. The relative risk of the event was calculated. A 95% confidence interval was used. Results and conclusion. A retrospective analysis showed that, firstly, CAP is a fairly frequent complication of COPD: initially, the average percentage of cases of САР was 19.3%. Secondly, the risk of developing repeated episodes of pneumonia remains quite high in unvaccinated patients and tends to increase within 5 years: from 17 to 22%. Thirdly, the pneumococcal vaccines used have different effects on the risk of recurrent pneumonia in patients with COPD, a significant decrease in the number of recurrent pneumonia is observed only with the use of conjugated vaccines.

show abstract

Effect of Community-Acquired Pneumonia on Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Cited by 6 publications

References 34 publications

Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) – A Systematic Review

Predictors of Readmission, for Patients with Chronic Obstructive Pulmonary Disease (COPD) – A Systematic Review

A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients

Impact of vaccination with pneumococcal vaccines on recurrent pneumonia in patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About